TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB91566

Peptide_Name

MAP-04-03

Activity

Antibacterial Anticancer Antifungal Hemolysis Toxicity

Activity_category_statistics

Anti-infective peptides Cancer-related peptides Toxicity and safety peptides

Database_Source

AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF pep-lab Antifungipept CAFPdb HemoPI Hemolytic2 PD_Hemolysis

Sequence_Type

standard

Has_Modification No

Description A 11-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

KWLRRVWRWWR-NH2

FASTA

>TPDB91566|Antibacterial;Anticancer;Antifungal;Hemolysis;Toxicity|length=11
KWLRRVWRWWR-NH2

Formula C85H122N28O12

Absent Amino Acids ANDCEQGHIMFPSTY

Common Amino Acids RW

Mass 1728.08

PI 12.88

Basic Residues 5

Acidic Residues 0

Hydrophobic Residues 6

Net Charge +5

Boman Index -3.66

Hydrophobicity -1.591

Aliphatic Index 61.82

Half Life

Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 22000

Absorbance 280nm 1273.09

Polar Residues 0

number

0

A

4

R

0

N

0

D

0

C

0

E

0

Q

0

G

0

H

0

I

1

L

1

K

0

M

0

F

0

P

0

S

0

T

4

W

0

Y

1

V

Amino Acid Distribution

A: 0 R: 4 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 1 K: 1 M: 0 F: 0 P: 0 S: 0 T: 0 W: 4 Y: 0 V: 1

Length

11

Formula

C85H122N28O12

Mass

1728.08

PI

12.88

Net Charge

+5

Boman Index

-3.66

Hydrophobicity

-1.591

C_terminal_Modification

Amidation

Chirality

L

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Antimicrobial

Origin

Analogs of Ixosin-B amide

Evidence 1 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >80% at 25 µM

Detail Source Activity Anticancer

Activity Measurement >80 % at 25 µM

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability ~50% at 50 µM

Detail Source Activity Anticancer

Activity Measurement ~50 % at 50 µM

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 3 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability <40% at 75 µM

Detail Source Activity Anticancer

Activity Measurement <40 % at 75 µM

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 4 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >20% at 100 µM

Detail Source Activity Anticancer

Activity Measurement >20 % at 100 µM

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 5 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability ~100% at 25 µM

Detail Source Activity Anticancer

Activity Measurement ~100 % at 25 µM

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 6 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=61.5 µM

Detail Source Activity Anticancer

Activity Measurement 61.5 µM

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013